Looking for markers that could help detect and predict pancreatic cancer
Searches for biomarkers that may help find and track pancreatic cancer in adults.
Plain-language title generated from the registry record
Registry title: BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC")
Key facts
- Where
- Herlev, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pancreatic cancer, including cancer of the ampulla, who are being studied for new biomarkers.
- Age
- Older than 18 years (the registry lists a minimum age of 19 years).
- Sex
- All sexes can join.
- Disease stage
- Pancreatic cancer (ductal adenocarcinoma) or ampullary adenocarcinoma, at any stage.
Read by machine on 9 November 2026.
Where in Denmark
- Herlev & Gentofte HospitalHerlev, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Inna Chen, MD
- Trial code
- NCT03311776
- Record updated
- 1 March 2023
- Original description
No validated biomarkers to identify PC at an early stage and to predict treatment outcomes in the individual patient exist. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.Read full original descriptionShow less
BIOmarkers in Patients With PAncreatic Cancer (BIOPAC) - Can They Provide New Information of the Disease and Improve Diagnosis and Prognosis of the Patients?
No validated biomarkers to identify PC at an early stage and to predict treatment outcomes in the individual patient exist. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.
Inclusion: Age > 18 years; Histologically verified PC (ductal adenocarcinoma) or ampullary adenocarcinoma in a resected specimen; or histopathological confirmation of carcinoma in patients not undergoing surgery in the setting of clinical and radiological characteristics which, together with the pathology, are consistent with a diagnosis of PC independently of stage.
Exclusion: None.